FDA
-
-
-
-
-
-
-
Palatin Technologies closes $18.2 million public offering
-
-
-
-
-
-
-
Palatin Presents Promising Preclinical Data on Melanocortin Agonists for Retinopathy at ARVO 2025
-
-
-
-
-
-
-
Palatin Announces Breakthrough Symptom Resolution in Updated Analyses from Phase 3 PL9643 MELODY-1 Clinical Trial in Dry Eye Disease
-
-
-
-
-
-
-
Palatin Technologies (PTN) Announces Positive Topline Results from Phase 2 Ulcerative Colitis Study of PL8177
-
-
-
-
-
-
-
Palatin Technologies (PTN) Completes Phase 2 Obesity Study With MC4R Bremelanotide Plus GLP-1/GIP Tirzepatide
-
-
-
-
-
-
-
Palatin Announces Exercise of Warrants for Approximately $3.4 Million Gross Proceeds
-
-
-
-
-
-
-
Palatin Technologies (PTN) Actively Engaged With Multiple Parties for Potential Funding Sources for Future Operating Cash Needs
-
329,074 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

